Alan Mateo
10x GenomicsAbout Alan Mateo
Independent director at 10x Genomics (TXG), age 63, appointed June 18, 2024 as a Class II director with a term expiring at the 2027 annual meeting . Serves on the Nominating & Corporate Governance Committee; the Board has determined he is independent under Nasdaq rules . He holds a BS in Computer Science and Marketing from Juniata College, with senior commercial leadership experience across life sciences software and enterprise applications .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Veeva Systems | Advisor; previously EVP, Global Sales | Advisor (current); EVP Apr 2015–Apr 2024 | Commercial leadership in life sciences software |
| Medidata Solutions | Executive roles incl. EVP Field Operations | Mar 2005–Feb 2015; EVP Jan 2014–Feb 2015 | Led field operations for cloud life sciences platform |
| PeopleSoft | Various executive roles in sales/ops | Nine years (dates not specified) | Product line sales, sales ops; JD Edwards integration |
| Red Pepper Software | Northeast Sales Director | Not disclosed | Supply chain planning software sales leadership |
| JD Edwards | Major Account Executive | Not disclosed | Strategic enterprise software accounts |
External Roles
| Organization | Role | Public Company Board? | Notes |
|---|---|---|---|
| Veeva Systems | Advisor | No | Prior EVP Global Sales; currently advisor |
| Other boards | — | None disclosed | Proxy does not list any current public company directorships for Mateo |
Board Governance
- Committees: Nominating & Corporate Governance Committee member (committee reconstituted Dec 19, 2024; chaired by Dr. Suliman) .
- Independence: Board affirms Mateo is independent; all key board committees are fully independent .
- Attendance: In 2025, the board met five times; each director attended at least 75% of board and applicable committee meetings .
- Leadership: Independent Chair (John Stuelpnagel); separate Chair/CEO; executive sessions for non-employee directors; majority voting standard .
- Risk oversight: Nominating & Governance oversees board independence and conflicts; Audit oversees accounting/cyber; Compensation oversees pay risk .
Fixed Compensation
| Component | Policy Detail | 2024 Actual (Cash) |
|---|---|---|
| Annual cash retainer | $55,000, paid quarterly, prorated | $29,641 (partial-year service; appointed June 18, 2024) |
| Committee member fee | Nominating & Governance member: $5,000 annually; chair $12,500 | Included in cash fees (prorated) |
| Chair retainers | Board Chair $50,000; Audit Chair $25,000; Comp Chair $18,250 | Not applicable (Mateo not chair) |
Notes: Directors are not paid meeting fees; travel reimbursed .
Performance Compensation
Directors receive time-based RSUs; no performance metrics apply to director equity grants. RSUs accelerate upon change-in-control, and annual grants vest quarterly; initial grant vests 1/3 at first anniversary then quarterly .
| Award Type | Grant Date | Number of RSUs | Grant Date Fair Value | Vesting | Performance Conditions |
|---|---|---|---|---|---|
| Initial RSU (onboarding) | Jul 31, 2024 | 21,691 | $400,000 target value per policy | 1/3 on Aug 21, 2025; then equal quarterly installments over two years | None (time-based) |
| Annual RSU (FY2025) | Jun 3, 2025 | 15,357 | ~$215,000 target value per policy (shares sized by 20-day avg price) | Quarterly vest over year post-grant | None (time-based) |
| Change-in-control | N/A | N/A | N/A | RSUs vest in full immediately prior to a change-in-control | N/A |
Citations for transactions: Initial RSU on 7/31/2024 (Form 4) , Annual RSU on 6/3/2025 (Form 4) .
Other Directorships & Interlocks
| Person | External Company | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Alan Mateo | Veeva Systems | Advisor | No related-party transactions disclosed; no payments to entities linked to Mateo beyond normal director compensation |
Expertise & Qualifications
- Background: Senior sales/commercial executive in life sciences software; enterprise applications experience; advisor at Veeva Systems .
- Education: BS in Computer Science and Marketing, Juniata College .
- Board skills matrix: Executive leadership, public company executive experience, life sciences, international business, business operations/development, strategic & portfolio planning, corporate governance .
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership (Mar 31, 2025) | 40,000 Class A shares, <1% of outstanding; no Class B |
| RSUs outstanding (Dec 31, 2024) | 21,691 RSUs; no outstanding options |
| Insider transactions | Form 3 filed upon appointment (Jun 18, 2024) ; RSU award 21,691 (Jul 31, 2024) ; Open-market purchase 40,000 shares @ $11.1393 (Feb 21, 2025) ; Annual RSU award 15,357 (Jun 3, 2025) |
| Post-transaction holdings | 77,048 securities owned after the Jun 3, 2025 RSU award (per Form 4 “securitiesOwned”) |
| Ownership guidelines | Directors must hold ≥3x annual cash retainer; compliance required by Jan 25, 2029 or within 5 years of appointment; company states each director satisfies or is making timely progress |
No pledging or hedging permitted; company prohibits short sales, derivative hedging, and pledging without preclearance .
Governance Assessment
- Committee assignments and engagement: Immediate placement on the Nominating & Corporate Governance Committee indicates focus on board composition, independence reviews, and governance process oversight .
- Independence and attendance: Board designates Mateo as independent; each director met ≥75% attendance in 2025—baseline engagement standard met .
- Compensation mix and alignment: Majority of 2024 compensation delivered via equity ($448,353 stock awards vs $29,641 cash), consistent with shareholder alignment; RSUs are time-based with CIC acceleration (standard market terms) .
- Ownership signals: Open-market purchase of 40,000 shares in Feb 2025 at ~$11.14 suggests personal capital at risk; post-transaction beneficial holdings increased (positive alignment indicator) .
- Conflicts/related party exposure: Proxy discloses no related-party transactions >$120k involving directors beyond ordinary compensation; formal policy requires Audit Committee pre-approval for any such transactions .
- Shareholder sentiment context: 2024 say-on-pay approval was ~83%, indicating supportive governance climate; not director-specific but relevant to overall board oversight credibility .
Director Compensation (Detail)
| Year | Fees Earned (Cash) | Stock Awards (Fair Value) | Total |
|---|---|---|---|
| 2024 | $29,641 | $448,353 | $477,994 |
Policy summary: Annual cash retainer $55,000; Nominating & Governance member $5,000; initial RSU grant $400,000; annual RSU grant $215,000; equity vests quarterly and accelerates upon change-in-control .
Insider Trades (Chronology)
| Transaction Date | Type | Shares/Units | Price | Post-Transaction Holdings | Source |
|---|---|---|---|---|---|
| Jun 18, 2024 | Form 3 (appointment) | — | — | — | |
| Jul 31, 2024 | RSU Award | 21,691 | $0 | 21,691 | |
| Feb 21, 2025 | Purchase (Open Market) | 40,000 | $11.1393 | 61,691 | |
| Jun 3, 2025 | RSU Award (Annual) | 15,357 | $0 | 77,048 |
Related Policies
- Clawback: SEC/Nasdaq-compliant clawback policy applies to incentive compensation; equity plan subject to recoupment .
- Prohibition on hedging/pledging: Directors and insiders prohibited from hedging and short sales; pledging requires preclearance; margin accounts prohibited .
- Stock ownership guidelines: Directors ≥3x cash retainer; compliance by Jan 25, 2029 or within 5 years from appointment .
Notes on Board Context
- Board composition: Eight directors, staggered terms; skills matrix highlights Mateo’s governance and commercial credentials; independent Chair .
- Committee independence: Audit, Compensation, and Nominating & Governance comprised entirely of independent directors .
- Meeting cadence and engagement: Five board meetings in 2025; executive sessions included in regular agendas .
RED FLAGS: None disclosed specific to Mateo—no related-party transactions; compliance practices robust (ownership guidelines, hedging ban). Positive ownership alignment via open-market purchase. Ongoing advisory role at Veeva disclosed; no transactional ties reported with TXG .